Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells

Oncogene

Volumn 27, Issue 29, 2008, Pages 4034-4043

  Qiu, W ^a   Wu, J ^a   Walsh, E M ^a   Zhang, Y ^a   Chen, C Y ^a,c   Fujita, J ^b   Xiao, Z X J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Gankyrin; MDM2; p53; Retinoblastoma protein

Indexed keywords

CASPASE 3; CISPLATIN; DOXORUBICIN; GANKYRIN; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION;

EID: 46449102332     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.43     Document Type: Article

References (40)

1. Argentini M, Barboule N, Wasylyk B. (2001). The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene 20: 1267-1275.
2. Beroud C, Soussi T. (1998). p53 gene mutation: software and database. Nucleic Acids Res 26: 200-204.
3. Bond GL, Hu W, Levine AJ. (2005). MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5: 3-8.
4. Classon M, Harlow E. (2002). The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2: 910-917.
5. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX et al. (1997). Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57: 1217-1221.
6. Dawson S, Higashitsuji H, Wilkinson AJ, Fujita J, Mayer RJ. (2006). Gankyrin: a new oncoprotein and regulator of pRb and p53. Trends Cell Biol 16: 229-233.
7. de Bruin A, Wu L, Saavedra HI, Wilson P, Yang Y, Rosol TJ et al. (2003). Rb function in extraembryonic lineages suppresses apoptosis in the CNS of Rb-deficient mice. Proc Natl Acad Sci USA 100: 6546-6551.
8. Dick FA, Dyson N. (2003). pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol Cell 12: 639-649.
9. Gotz C, Kartarius S, Scholtes P, Nastainczyk W, Montenarh M. (1999). Identification of a CK2 phosphorylation site in mdm2. Eur J Biochem 266: 493-501.
10. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H et al. (2003). Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300: 342-344.
11. Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX et al. (1998). p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 2: 405-415.
12. Haupt Y, Maya R, Kazaz A, Oren M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
13. Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T et al. (2000). Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 6: 96-99.
14. Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo Y, Masuda T et al. (2005). The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 8: 75-87.
15. Hjerrild M, Milne D, Dumaz N, Hay T, Issinger OG, Meek D. (2001). Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells. Biochem J 355: 347-356.
16. Hsieh JK, Chan FS, O'Connor DJ, Mittnacht S, Zhong S, Lu X. (1999). RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 3: 181-193.
17. Kawai H, Wiederschain D, Yuan ZM. (2003). Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 23: 4939-4947.
18. Kubbutat MH, Jones SN, Vousden KH. (1997). Regulation of p53 stability by Mdm2. Nature 387: 299-303.
19. Kulikov R, Boehme KA, Blattner C. (2005). Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol 25: 7170-7180.
20. Kulikov R, Winter M, Blattner C. (2006). Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J Biol Chem 281: 28575-28583.
21. Lipinski MM, Macleod KF, Williams BO, Mullaney TL, Crowley D, Jacks T. (2001). Cell-autonomous and non-cell-autonomous functions of the Rb tumor suppressor in developing central nervous system. EMBO J 20: 3402-3413.
22. Ma J, Martin JD, Zhang H, Auger KR, Ho TF, Kirkpatrick RB et al. (2006). A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry 45: 9238-9245.
23. Meulmeester E, Frenk R, Stad R, de Graaf P, Marine JC, Vousden KH et al. (2003). Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 23: 4929-4938.
24. Oren M. (2003). Decision making by p53: life, death and cancer. Cell Death Differ 10: 431-442.
25. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L et al. (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
26. Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R et al. (2005). MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20: 699-708.
27. Sdek P, Ying H, Zheng H, Margulis A, Tang X, Tian K et al. (2004). The central acidic domain of MDM2 is critical in inhibition of retinoblastoma protein-mediated suppression of E2F and cell growth. J Biol Chem 279: 53317-53322.
28. Sherr CJ. (2004). Principles of tumor suppression. Cell 116: 235-246.
29. Sherr CJ, McCormick F. (2002). The RB and p53 pathways in cancer. Cancer Cell 2: 103-112.
30. Stevaux O, Dyson NJ. (2002). A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol 14: 684-691.
31. Sui G, Affar el B, Shi Y, Brignone C, Wall NR, Yin P et al. (2004). Yin Yang 1 is a negative regulator of p53. Cell 117: 859-872.
32. Uchida C, Miwa S, Kitagawa K, Hattori T, Isobe T, Otani S et al. (2005). Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J 24: 160-169.
33. Vogelstein B, Kinzler KW. (2004). Cancer genes and the pathways they control. Nat Med 10: 789-799.
34. Wang C, Ivanov A, Chen L, Fredericks WJ, Seto E, Rauscher III FJ et al. (2005). MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J 24: 3279-3290.
35. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. (1999). Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1: 20-26.
36. Wu L, de Bruin A, Saavedra HI, Starovic M, Trimboli A, Yang Y et al. (2003). Extra-embryonic function of Rb is essential for embryonic development and viability. Nature 421: 942-947.
37. Xiao ZX, Chen J, Levine A, Modjtahedi N, Xing J, Sellers W et al. (1995). Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698.
38. Xu HJ, Cagle PT, Hu SX, Li J, Benedict WF. (1996). Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. Clin Cancer Res 2: 1169-1176.
39. Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA et al. (2003). Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 23: 8902-8912.
40. Zhang Y, Xiong Y, Yarbrough WG. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.